Skip to main content
SpringerLink
Log in

Prevention of Acute Emesis from Other Emetogenic Drugs

  • Conference paper
Antiemetics in the Supportive Care of Cancer Patients

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 70 Accesses

Abstract

Although cisplatin is the most emetogenic cytotoxic agent, many other antineoplastic drugs are also able to induce moderate to severe emesis. Table 1 shows a ranking of the emetic potential of several antitumour agents different from cisplatin. It is important to point out that the final intensity of emesis is not only related to the intrinsic emetic capacity of the antitumour drug, but to other prognostic factors such as gender of the patient, previous chemotherapy-induced emesis, age, route, dose, schedule and setting of administration of the agent, combination with other emetic drugs, etc. [1,2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pater JL, Willan AR: Methodologic issues in trials of antiemetics. J Clin Oncol 1984 (2):484–487

    PubMed  CAS  Google Scholar 

  2. Tonato M, Roila F, Del Favero A: Methodology of antiemetic trials: A review. Ann Oncol 1991 (2):107–114

    PubMed  CAS  Google Scholar 

  3. Kris MG, Gralla RJ, Clark RA et al: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985 (3):1379–1384

    PubMed  CAS  Google Scholar 

  4. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ: Delayed emesis following high-dose cisplatin: a double-blind randomized comparative trial of ondansetron (GR38032F) versus placebo. Eur J Cancer 1993 (29A Suppl 1):S35–S38

    Article  PubMed  Google Scholar 

  5. Fetting JH, Grochow LB, Folstein MF, Ettinger DS, Colvin M: The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982 (66): 1487–1493

    PubMed  CAS  Google Scholar 

  6. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega JM: The natural course of emesis after carboplatin treatment. Acta Oncol 1990 (29):593–595

    Article  PubMed  CAS  Google Scholar 

  7. Martin M: Myths and realities of antiemetic treatment. Br J Cancer 1992 (66 Suppl XIX):S46–S51

    Google Scholar 

  8. Rosso R, Campora E, Cetto G, Fosser V, Marangolo M, Oliva C: Oral ondansetron for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res 1991 (11):937–939

    PubMed  CAS  Google Scholar 

  9. Schmoll HJ: The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimens. Eur J Cancer Clin Oncol 1989 (25 Suppl 1):S35–S39

    Article  PubMed  Google Scholar 

  10. Smith DB, Rustin GJ, Howells N, Lambert HE, McQuade B: A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. Ann Oncol 1991 (2):607–608

    PubMed  CAS  Google Scholar 

  11. Warr D, Willan A, Fine S et al: Superiority of grani-setron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. JNCI 1991 (83):1169–1173

    PubMed  CAS  Google Scholar 

  12. Smith IE on behalf of the Granisetron Study Group: A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 1990 (26 Suppl 1):S19–S22

    Google Scholar 

  13. Jones AL, Hill AS, Soukop M et al: Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991 (338):483–487

    Article  PubMed  CAS  Google Scholar 

  14. Borison HL, McCarthy LE: Neuropharmacology of chemotherapy-induced emesis. Drugs 1993 (25 Suppl 1):8–17

    Article  Google Scholar 

  15. Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL: Antagonism of serotonin S-3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 1990 (8): 1721–1727

    PubMed  CAS  Google Scholar 

  16. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombemofsky P: Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993 (328): 1076–1080

    Article  PubMed  CAS  Google Scholar 

  17. Marty M on behalf of the Granisetron Study Group: A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. Eur J Cancer 1992 (28A Suppl 1):S12–S16

    Google Scholar 

  18. Morrow GR, Loughner JE, Bennet JM: Prevalence of nausea and vomiting and other side effects in patients receiving Cytoxan, methotrexate, fluorouracil (CMF) therapy with and without prednisone. Proc ASCO 1984 (3):105

    Google Scholar 

  19. Buser K, Joss R, Piquet D et al: A randomized, double-blind comparison of oral ondansetron and placebo in the prophylaxis of CMF-induced nausea and vomiting. Proc ASCO 1990 (9):331

    Google Scholar 

  20. Levitt M, Warr D, Yelle L et al: Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and 5-fluoro-uracil. N Engl J Med 1993 (328):1081–1084

    Article  PubMed  CAS  Google Scholar 

  21. David M, Durand M, Chauvergne J, Mauriac L, Bui BN, Hoerni B: Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: A controlled study with high-dose metoclopramide. Cancer Treat Rep 1984 (68):921–922

    PubMed  CAS  Google Scholar 

  22. Roila F, Minotti V, Ballatori E, Basurto C, Tonato M: Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF. Tumori 1985(71):455–458

    CAS  Google Scholar 

  23. Chiara S, Campora E, Lionetto R, Bruzzi P, Rosso R: Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 1987 (10):264–267

    Article  PubMed  CAS  Google Scholar 

  24. Campora E, Oliva C, Mammoliti S et al: Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. Breast Cancer Res Treat 1991 (19): 129–132

    Article  PubMed  CAS  Google Scholar 

  25. Pollera CF, Nardi M, Marolla P, Pinaro P, Terzoli E, Giannarelli D: Effective control of CMF-related eme-sis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Am J Clin Oncol 1989 (12):524–529

    Article  PubMed  CAS  Google Scholar 

  26. Gez E, Sulkes A, Ochayon L et al: Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: A randomized crossover blind study. J Chemother 1989 (1):365–368

    PubMed  CAS  Google Scholar 

  27. Roila F, Basurto C, Minotti V, Ballatori E, Tonato M, Del Favero A: Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide, methotrexate, 5-fluorouracil: A double-blind, randomized study. Oncology 1988 (45):346–349

    Article  PubMed  CAS  Google Scholar 

  28. Campora E, Chiara S, Bruzzi P, Scarsi P, Rosso R: The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: A randomized trial. Tumori 1985 (71):459–462

    PubMed  CAS  Google Scholar 

  29. Silvey L, Carpenter JT, Wheeler RH, Lee J, Conolley C: A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. J Clin Oncol 1988 (6): 1397–1400

    PubMed  CAS  Google Scholar 

  30. Martin M, Aranda E, Diaz-Rubio E et al: Emetic control in breast cancer patients receiving i.v. CMF: Results of two consecutive studies using a new method of assessment. Oncology Rep 1996 (3): 115–121

    CAS  Google Scholar 

  31. Martin Jimenez M, Diaz-Rubio E, Blazquez Encinar JC et al: Tolerancia, toxicidad y aceptación del tratamiento quimioterápico FAC (5-fluorouracilo, adriamicina y ciclofosfamida) en el cáncer de mama. Análisis de 100 pacientes consecutivas. Neoplasia 1988(5):8–14

    Google Scholar 

  32. Edge SB, Funkhouser WK, Berman A et al: High-dose oral and intravenous metoclopramide in doxo-rubicin/cyclophosphamide-induced emesis. Am J Clin Oncol 1987 (10):257–263

    Article  PubMed  CAS  Google Scholar 

  33. Diaz-Rubio E, Martin M, Roseli R, Valerdi JJ, Gonzalez-Larriba JL, Barriga JJ: The antiemetic efficacy of thyethylperazine and methylpredni-solone versus thyethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide). A randomized, double-blind, cross-over trial. Acta Oncologica 1991 (30):339–342

    Article  PubMed  CAS  Google Scholar 

  34. Martin M, Diaz-Rubio E, Casado A, Domínguez S, Sastre J: Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. Eur J Cancer 1992 (28):430–432

    Article  PubMed  CAS  Google Scholar 

  35. Bonneterre J, Kerbrat P, Fargeot P et al: A multicen-ter randomized cross-over trial comparing methyl-prednisolone (120 mg, IV) to beta-1–24 ACTH (0.5 mg, IM) in the prophylaxis of emesis induced by FEC regimen. Proc ASCO 1990 (9): 1231

    Google Scholar 

  36. Fraschini G, Ciociola A, Esparza L et al: Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 1991 (9):1268–1274

    PubMed  CAS  Google Scholar 

  37. Bonneterre J, Chevalier B, Metz R et al: A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990(8):1063–1069

    PubMed  CAS  Google Scholar 

  38. Kaasa S, Kvaloy S, Dicato MA et al: A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study. Eur J Cancer 1990 (26):311–314

    Article  PubMed  CAS  Google Scholar 

  39. Dicato MA, Kaasa S, Campora E et al: Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy-induced emesis: A randomized, single-blind, multicentre study. The Ondansetron International Study Group. Clin Oncol (R Coll Radiol) 1992 (4):275–279

    Article  CAS  Google Scholar 

  40. Campora E, Giudici S, Merlini L, Rosso R: Control of acute, delayed FEC/FAC-induced emesis and GI toxicity at subsequent cycles: A randomized trial of metoclopramide, dexamethasone and orphenadrine vs ondansetron and dexamethasone. Proc ASCO 1992 (11): 1358

    Google Scholar 

  41. Harvey VJ, Evans BD, Mitchell PLR et al: Reduction of carboplatin induced emesis by ondansetron. Br J Cancer 1991 (63):942–944

    Article  PubMed  CAS  Google Scholar 

  42. Gridelli C, Incoronato P, Airona G, Pepe R, Arpinelli F, Bianco AR: Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy. Eur J Cancer 1993 (29A):651

    PubMed  CAS  Google Scholar 

  43. Tyson LB, Clark RA, Gralla RJ: High-dose metoclopramide: Control of dacarbazine-induced emesis in a preliminary trial. Cancer Treat Rep 1982 (66): 2108

    PubMed  CAS  Google Scholar 

  44. Basurto C, Roila F, Tonato M, Ballatori E, Buzzi F, Calabresi F, Del Favero A: Antiemetic activity of high-dose metoclopramide combined with methyl-prednisolone versus metoclopramide alone in dacar-bazine-treated cancer patients. Am J Clin Oncol 1989(12):235–238

    Article  PubMed  CAS  Google Scholar 

  45. Green JA, Watkin SW, Hammond P, Griggs, Challoner T: The efficacy and safety of GR38032F in the prophylaxis of ifosfamide induced nausea and vomiting. Cancer Chemother Pharmacol 1989 (23 Suppl):67

    Google Scholar 

  46. Dokati D, Gilli G, Indelli M, Marzola M, Santini A, Malacarne P: Methylprednisolone in control of 4’-epidoxorubicin-induced emesis. Proceedings ECCO-4 (Fourth European Conference on Clinical Oncology and Cancer Nursing). Madrid, November 1987 p281

    Google Scholar 

  47. Moertel CG, Reitemeier RJ, Gage RP: A controlled clinical evaluation of antiemetic drugs. JAMA 1963 (186):116–118

    Google Scholar 

  48. Moertel CG, Reitemeier RJ: Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology 1969 (57):262–268

    PubMed  CAS  Google Scholar 

  49. Chang AE, Shiling DJ, Stillman RC et al: Dealta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979 (91):819–824

    PubMed  CAS  Google Scholar 

  50. Craig JB, Powell BL, White DR, Capizzi RL: Antiemetic therapy in patients treated with high-dose cytosine arabinoside. Oncology 1987 (44):90–92

    Article  PubMed  CAS  Google Scholar 

  51. The Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995 (332): 1–5

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Universitario San Carlos, 28040, Madrid, Spain

    Miguel Martin & Eduardo Díaz-Rubio

Authors
  1. Miguel Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduardo Díaz-Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Oncology Division, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Maurizio Tonato M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Martin, M., Díaz-Rubio, E. (1996). Prevention of Acute Emesis from Other Emetogenic Drugs. In: Tonato, M. (eds) Antiemetics in the Supportive Care of Cancer Patients. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80240-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80240-9_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80242-3

  • Online ISBN: 978-3-642-80240-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation